ScholarLens Back to search
2014•Formulary ENewsRequires access

First-oral therapy approved for adults with active psoriatic arthritis

Tracey Walker

Open publisher page 0 citations

Abstract

FDA has approved apremilast (Otezla, Celgene), an oral, selective inhibitor of phosphodiesterase 4 (PDE4) to treat adults with active psoriatic arthritis (PsA).

About this research paper

What this paper is about

FDA has approved apremilast (Otezla, Celgene), an oral, selective inhibitor of phosphodiesterase 4 (PDE4) to treat adults with active psoriatic arthritis (PsA).

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

FDA has approved apremilast (Otezla, Celgene), an oral, selective inhibitor of phosphodiesterase 4 (PDE4) to treat adults with active psoriatic arthritis (PsA).

Key concepts: Psoriatic arthritis, Medicine, Dermatology, Psoriasis

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
First-oral therapy approved for adults with active psoriatic arthritis — Research Paper | ScholarLens